INTI

$0.08-18.56%visit website

Inhibitor Therapeutics, Inc.

Market Cap

$14M

Live price × SEC shares (Aug 14, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

-0.73

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	378	757	341	224	1,699
Total operating expenses	741	1,315	696	619	3,371
Operating income	(741)	(1,315)	(696)	(619)	(3,371)
Net income	(712)	(1,295)	(686)	(614)	(3,308)
EPS (basic) ($)	0.00		0.00	0.00	(0.02)
EPS (diluted) ($)	0.00		0.00	0.00	(0.02)
Weighted avg. shares (basic)	172,574		172,574	173,308
Weighted avg. shares (diluted)	172,574		172,574	173,308

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 52 more quarters, back to Sep 2012, with Tormere Pro.

Corporate Events (8-K)

4 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Sep 18, 2026 accepted 4:00 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
Apr 1, 2026 accepted 4:05 PM ET	7.01Reg FD disclosure	Document SEC ↗
Apr 1, 2026 accepted 8:00 AM ET	8.01Other events	Document SEC ↗
Feb 24, 2026 accepted 8:00 AM ET	1.01Material agreement	Document SEC ↗
Oct 27, 2025 accepted 8:34 PM ET	1.01Material agreement5.02Officer / director change	Document SEC ↗